Table 1 The basic demographic and disease characteristics
From: Sorafenib inhibits interferon production by plasmacytoid dendritic cells in hepatocellular carcinoma
HCC + Sroafenib n = 14 | HCC n = 28 | P | |
|---|---|---|---|
Median age (range) | 57 years (36–74 years) | 51 years (38–74 years) | > 0.05 |
gender | |||
Male | 14 | 23 | > 0.05 |
Female | – | 5 | – |
HBV infection | 6 | 12 | > 0.05 |
HCV infection | – | – | |
Recurrence HCC | 14 | 28 | > 0.05 |
Prior anticancer treatment | |||
Yes | 14 | 28 | > 0.05 |
No | – | – | – |
BCLC stage | |||
A | – | – | – |
B | – | – | – |
C | 14 | 28 | > 0.05 |
Child-Pugh | |||
A | 14 | 28 | > 0.05 |
B | – | – | – |
C | |||
Ascites | no | no | – |
White blood cell count | 4.6 × 109 | 5.6 × 109 | > 0.05 |